Disease · HP_0001750

Single ventricle

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Single ventricle. Diseases, record HP_0001750. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001750

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Single ventricle
Open Targets ID: HP_0001750
Other names: Common ventricle
Highest stage of its drugs: Phase 3, for 1 of its 2 drugs, from ClinicalTrials.gov

Source Open Targets

Drugs2

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ENALAPRIL	CHEMBL578	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SILDENAFIL	CHEMBL192	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets2

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ACE	Angiotensin-converting enzyme	1	Angiotensin-converting enzyme inhibitor	Phase 3	https://conductscience.org/library/genes/1636	Drugs and targets
PDE5A	cGMP-specific 3',5'-cyclic phosphodiesterase	1	Phosphodiesterase 5A inhibitor	Phase 1	https://conductscience.org/library/genes/8654	Drugs and targets

Trials2

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00113087	Trial of Angiotensin Converting Enzyme Inhibition in Infants With Single Ventricle--Pediatric Heart Network	Phase 3	230	2010-09-16	Heart Defects, Congenital, Heart Failure, Congestive	ENALAPRIL	Its record names the disease	ClinicalTrials.gov
NCT01169519	Sildenafil in Single Ventricle Patients	Phase 1	21	2013-12-05	Heart Disease	SILDENAFIL	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Enalapril vs Placebo: serious adverse events	88 of 115	87 of 115	230	NCT00113087	Trial comparisons
Enalapril vs Placebo: Number of Participants With Ross Heart Failure Class I	53 of 96	56 of 102	198	NCT00113087	Trial comparisons
Enalapril vs Placebo: Number of Participants With Moderate to Severe AV Valve Regurgitation	20 of 98	32 of 98	196	NCT00113087	Trial comparisons
Enalapril vs Placebo: Number of Participants With Ross Heart Failure Class I	72 of 91	77 of 94	185	NCT00113087	Trial comparisons
Enalapril vs Placebo: Number of Participants With Moderate to Severe AV Valve Regurgitation	11 of 90	22 of 93	183	NCT00113087	Trial comparisons

Papers from its trials10

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
23823195	RESULT	1	PubMed
26490132	DERIVED	1	PubMed
24201857	DERIVED	1	PubMed
22939929	DERIVED	1	PubMed
22939855	DERIVED	1	PubMed
22931751	DERIVED	1	PubMed
21784436	DERIVED	1	PubMed
21576655	DERIVED	1	PubMed
20625111	DERIVED	1	PubMed
19081394	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0001750

GET https://conductscience.org/api/diseases/v1/HP_0001750/drugs

API reference For AI assistants